Pagani, I.; Ottoboni, L.; Panina-Bordignon, P.; Martino, G.; Poli, G.; Taylor, S.; Turnbull, J.E.; Yates, E.; Vicenzi, E.
Heparin Precursors with Reduced Anticoagulant Properties Retain Antiviral and Protective Effects That Potentiate the Efficacy of Sofosbuvir against Zika Virus Infection in Human Neural Progenitor Cells. Pharmaceuticals 2023, 16, 1385.
https://doi.org/10.3390/ph16101385
AMA Style
Pagani I, Ottoboni L, Panina-Bordignon P, Martino G, Poli G, Taylor S, Turnbull JE, Yates E, Vicenzi E.
Heparin Precursors with Reduced Anticoagulant Properties Retain Antiviral and Protective Effects That Potentiate the Efficacy of Sofosbuvir against Zika Virus Infection in Human Neural Progenitor Cells. Pharmaceuticals. 2023; 16(10):1385.
https://doi.org/10.3390/ph16101385
Chicago/Turabian Style
Pagani, Isabel, Linda Ottoboni, Paola Panina-Bordignon, Gianvito Martino, Guido Poli, Sarah Taylor, Jeremy E. Turnbull, Edwin Yates, and Elisa Vicenzi.
2023. "Heparin Precursors with Reduced Anticoagulant Properties Retain Antiviral and Protective Effects That Potentiate the Efficacy of Sofosbuvir against Zika Virus Infection in Human Neural Progenitor Cells" Pharmaceuticals 16, no. 10: 1385.
https://doi.org/10.3390/ph16101385
APA Style
Pagani, I., Ottoboni, L., Panina-Bordignon, P., Martino, G., Poli, G., Taylor, S., Turnbull, J. E., Yates, E., & Vicenzi, E.
(2023). Heparin Precursors with Reduced Anticoagulant Properties Retain Antiviral and Protective Effects That Potentiate the Efficacy of Sofosbuvir against Zika Virus Infection in Human Neural Progenitor Cells. Pharmaceuticals, 16(10), 1385.
https://doi.org/10.3390/ph16101385
